Randall E. Woods is President and Chief Executive Officer of Sophiris Bio Inc. Mr. Woods joined Sophiris as Chief Executive Officer in August 2012 and brings with him 40 years of biotech and pharmaceutical leadership experience. Prior to joining Sophiris, Mr. Woods was President and CEO of Sequel Pharmaceuticals, a spinout of NovaCardia developing a potential treatment for atrial fibrillation. Mr. Woods was previously the President and CEO of NovaCardia, a pharmaceutical company focused on cardiovascular diseases, until its acquisition by Merck & Co. for $350 million in 2007. Prior to NovaCardia, Mr. Woods was President and CEO of Corvas International, a publicly traded biopharmaceutical company focused on cardiovascular disease and cancer until its acquisition by Dendreon in 2003. Before joining Corvas, he served as President of Boehringer Mannheim’s U.S. Pharmaceutical operations, and spent 20 years at Eli Lilly & Company in various sales and marketing positions. Mr. Woods is a past Chairman for the advisory board of UC San Diego’s Sulpizio Family Cardiovascular Center and is a past Chairman of the board of directors for BIOCOM, a life science industry association in Southern California. Mr. Woods also serves on the board of Arena Pharmaceuticals. He received his B.S. in biology and chemistry from Ball State University, and an MBA in marketing from Western Michigan University. Profile
TWST: Could we start out with a brief overview of the history and
evolution of Corvas International, Inc?
Mr. Woods: Corvas was founded in 1987 with a primary focus on